Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 while the study record continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check12 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden response.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden error, replacing the detailed study content with an error page. As a result, the trial's title, conditions, locations, documents, and other structured data become inaccessible in this view.SummaryDifference18%

- Check54 days agoChange DetectedThe page shows an updated Revision tag from v3.6.5 to v3.6.6. This appears to be a minor platform update and does not change the study details or how users interact with the page.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page revision has been updated to v3.6.5, replacing v3.6.4. This reflects an updated document state rather than changes to the study details or overall content.SummaryDifference0.0%

- Check89 days agoChange DetectedA publication citation in the Publications section was updated to reflect a 2026 July version with a DOI, replacing the earlier print/online-ahead-of-print entry. This is a bibliographic update rather than a change to study data or conduct.SummaryDifference0.1%

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.